AstraZeneca Investor Day Presentation Deck
Overall survival
Probability of OS
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Number of subjects at risk
Durvalumab + GemCis
Placebo + GemCis
341
344
HR for time up to
6 months (95% CI)
0.91 (0.66-1.26)
309
317
6
268
261
Durvalumab + GemCis (n=341)
Placebo + GemCis (n=344)
Statistical significance cut-off for OS: p=0.03
HR for time after
6 months (95% CI)
0.74 (0.58-0.94)
208
183
12-mo OS:
54.1%
48.0%
135
125
Median OS
(95% CI), months
12.8 (11.1-14.0)
11.5 (10.1-12.5)
15
18
12
Time from randomization (months)
79
49
65
29
12 Median duration of follow-up (95% Cl) was 16.8 (14.8-17.7) months with durvalumab + GemCis and 15.9 (14.9-16.9) months with placebo + GemCis.
CI, confidence interval; GemCis, gemcitabine and cisplatin; HR, hazard ratio; mo, month; OS, overall survival.
18-mo OS:
35.1%
25.6%
21
24
10
Hazard ratio
(95% CI)
0.80
(0.66-0.97)
24
9
4
24-mo OS:
24.9%
10.4%
p-value
27
1
0
0.021
30
12View entire presentation